Gallelli Luca, Siniscalchi Antonio, Carotenuto Marco, Caroleo Maria C, Cione Erika, Guidetti Vincenzo
University of Catanzaro, Clinical Pharmacology Unit, Mater Domini University Hospital - Chair of Pharmacology, Department of Health Science, School of Medicine, Catanzaro. Italy.
Department of Neurology, Annunziata Hospital Via F. Migliori, 1; 87100 Cosenza. Italy.
Microrna. 2017;6(1):17-21. doi: 10.2174/2211536606666170104130101.
Among the clinical spectrum of neurological diseases, migraine is often associated with cerebro-vasculopathy. Impairment of neuroimmune mediators in the central nervous system has been recognized in the pathophysiology of migraine-related stroke. Although genetic correlation was found in patients with migraine-related stroke, the epidemiology of this disease indicates a need in biomarker searching discovery and validation. In this view, small molecule, called microRNAs (miRNAs), able to regulate immune and neuronal processes has been reported in patients with migraine and ischemic stroke and unambiguous miRNAs related to these diseases could be established as new molecular indicator of precocity for clinical and/or pharmacological intervention. Therefore, further exploration of this area is necessary, as greater understanding of these biomarkers could reveal the common mechanisms involved in the pathophysiology of migraine in patients with cerebral infarct.
在神经系统疾病的临床谱系中，偏头痛常与脑血管病变相关。中枢神经系统中神经免疫介质的损伤已在偏头痛相关性卒中的病理生理学中得到确认。尽管在偏头痛相关性卒中患者中发现了遗传相关性，但该疾病的流行病学表明需要寻找、发现和验证生物标志物。从这个角度来看，一种名为微小RNA（miRNAs）的小分子能够调节免疫和神经元过程，在偏头痛和缺血性卒中患者中已有报道，与这些疾病相关的明确的miRNAs可以作为临床和/或药物干预早熟的新分子指标。因此，有必要进一步探索这一领域，因为对这些生物标志物的更深入了解可能揭示脑梗死患者偏头痛病理生理学中涉及的共同机制。
